Ra Capital Management, a director and more than 10% owner of 89bio Inc. (ETNB), bought common stock worth $49.99 million last ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

SG Americas Securities LLC lifted its holdings in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 18.3% during the fourth quarter, ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Check Out Our Latest Report on 89bio 89bio Price Performance Shares of ETNB opened at $11.43 on Wednesday. The business’s 50 day moving average price is $7.94 and its two-hundred day moving ...

Wolfe Research initiated coverage of 89bio (ETNB) with an Outperform rating and $15 price target. Considering how low the stock is currently ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

89bio (NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a ...

The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with ...